Entasis Therapeutics Appoints David Meek as Chairman of the Board
“The Board and I are thankful to Dr. Galakatos for providing invaluable guidance to our leadership team as Chairman of the Board over the past several years and we will continue to benefit from his experience,” said Manos Perros, President and Chief Executive Officer of Entasis. “Additionally, we are very pleased to welcome
Mr. Meek has over 25 years of experience in the healthcare industry where he has held various global executive positions at major pharmaceutical and biotechnology companies. He is currently the Chief Executive Officer and Board member of
“I look forward to working closely with the Entasis board and management team and leveraging our collective experiences to build on the strong foundation Nick has established during his tenure as the Chairman of Entasis’ Board,” commented
Dr. Galakatos added, “I am grateful to have had the opportunity to serve as Chairman of the Entasis Board, and I am pleased to transition this role to David. Entasis is a very promising biopharmaceutical company and David is uniquely qualified to provide strategic guidance as we progress our multiple differentiated antimicrobial assets into the final stages of clinical development and prepare for commercialization. I will continue to work closely with the Board and the management team to advance and support the Company's growth.”
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact
Investor Relations Contacts
Tram Bui /
(646) 536-7035 / 7026
Source: Entasis Therapeutics Holdings Inc.